GR1000597B - Παραγοντας αναστολης αναπτυξης και χρηση του. - Google Patents

Παραγοντας αναστολης αναπτυξης και χρηση του.

Info

Publication number
GR1000597B
GR1000597B GR890100029A GR890100029A GR1000597B GR 1000597 B GR1000597 B GR 1000597B GR 890100029 A GR890100029 A GR 890100029A GR 890100029 A GR890100029 A GR 890100029A GR 1000597 B GR1000597 B GR 1000597B
Authority
GR
Greece
Prior art keywords
growth inhibitor
tissue
suspension agent
organic
compound
Prior art date
Application number
GR890100029A
Other languages
English (en)
Inventor
Judah Moses Folkman
Burg Paul Weisz
Original Assignee
Judah Moses Folkman
Burg Paul Weisz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Judah Moses Folkman, Burg Paul Weisz filed Critical Judah Moses Folkman
Publication of GR1000597B publication Critical patent/GR1000597B/el

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C07K14/503—Fibroblast growth factor [FGF] basic FGF [bFGF]
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/21—Acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/22—Lipids, fatty acids, e.g. prostaglandins, oils, fats, waxes
    • A61L2300/222—Steroids, e.g. corticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/80—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special chemical form
    • A61L2300/802—Additives, excipients, e.g. cyclodextrins, fatty acids, surfactants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Botany (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)

Abstract

Παθολογικά ή διαφορετικά ανεπιθύμητες αναπτύξεις ιστού ή κυττάρων σε θηλαστικά, περιλαμβανομένων ανθρώπων, αναστέλλονται με την χορήγηση σε αυτά μιας σύνθεσης που δίνεται ως παράδειγμα από (1) ένα ευδιάλυτο σε νερό θειϊκό αλάτι κυκλοδεξτρίνης, μαζί με (2) μια οργανική ένωση αναστολής ανάπτυξης. Η ένωση αναστολής ανάπτυξης (2) μπορεί να είναι ένα στεροειδές έχοντας μη ανασταλτική αποτελεσματικότητα με απουσία του (1), ή μια οργανική ένωση που μπορεί να είναι ένας ενεργός αναστολέας ανάπτυξης, η δράση της οποίας δυναμικοποιείται από (1). Η εφεύρεση παρέχει μια μέθοδο ανστολής αγγειογένεσης και ελέγχου της ανάπτυξης νεοπλασμάτων καθώς και θεραπείας άλλων διαταραχών και παθολογικών καταστάσεων που συνδυάζονται με ανεπιθύμητη ανάπυξη ιστών και κυττάρων, περιλαμβανομένης της αγγειογένεσης. ω
GR890100029A 1988-01-19 1989-01-17 Παραγοντας αναστολης αναπτυξης και χρηση του. GR1000597B (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14540788A 1988-01-19 1988-01-19
US29563889A 1989-01-10 1989-01-10

Publications (1)

Publication Number Publication Date
GR1000597B true GR1000597B (el) 1992-08-26

Family

ID=26842946

Family Applications (1)

Application Number Title Priority Date Filing Date
GR890100029A GR1000597B (el) 1988-01-19 1989-01-17 Παραγοντας αναστολης αναπτυξης και χρηση του.

Country Status (11)

Country Link
EP (1) EP0398925B1 (el)
JP (1) JP2995069B2 (el)
KR (1) KR900700114A (el)
CN (1) CN1038304C (el)
DE (1) DE68910113T2 (el)
DK (1) DK171390A (el)
ES (1) ES2017808A6 (el)
GR (1) GR1000597B (el)
IE (1) IE64346B1 (el)
IL (1) IL88970A (el)
WO (1) WO1989006536A1 (el)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5183809A (en) * 1990-02-15 1993-02-02 The Trustees Of The University Of Pennsylvania/Childrens Hospital Corporation Cyclodextrin polymers and cyclodextrins immobilized on a solid surface
US5637575A (en) * 1988-01-19 1997-06-10 The Trustees Of The University Of Pennsylvania Methods of inhibiting restenosis
US5658894A (en) * 1989-04-23 1997-08-19 The Trustees Of The University Of Pennsylvania Compositions for inhibiting restenosis
US5760015A (en) * 1988-01-19 1998-06-02 The Trustees Of The University Of Pennsylvania Cyclodextrin compounds and methods of making and use thereof
CA2008534A1 (en) * 1989-01-26 1990-07-26 Donald E. Ingber Method for inhibiting tumor recurrence after surgical resection
US5173481A (en) * 1989-04-03 1992-12-22 The United States Of America As Represented By The Department Of Health And Human Services Preparation of specifically substituted cyclodextrins
US5441944A (en) * 1989-04-23 1995-08-15 The Trustees Of The University Of Pennsylvania Substituted cyclodextrin sulfates and their uses as growth modulating agents
EP0518930A4 (en) * 1990-03-02 1993-09-15 Australian Commercial Research & Development Limited Cyclodextrin compositions and methods for pharmaceutical and industrial applications
US5227372A (en) * 1990-03-07 1993-07-13 Children's Medical Center Corporation Method for retaining ophthalmological agents in ocular tissues
TW282399B (el) * 1990-05-25 1996-08-01 Takeda Pharm Industry Co Ltd
US5446030A (en) * 1991-09-19 1995-08-29 Weisz; Paul B. Prevention of hemolysis
BR9405858A (pt) * 1993-03-31 1995-12-12 Univ Pennsylvania Processos de afetar o crescimento de tecido vivo em mamiferos compostos e composiçÕes para os mesmos
CN1502331A (zh) * 1993-07-19 2004-06-09 Ѫ�ܼ���ҩ�﹫˾ 抗血管生长组合物及使用方法
US5753230A (en) * 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
US7053041B1 (en) 1996-05-31 2006-05-30 The Scripps Research Institute Methods and compositions useful for inhibition of αvβ5mediated angiogenesis
PT951295E (pt) 1996-05-31 2010-07-29 Scripps Research Inst COMPOSIÎES PARA UTILIZAÆO NA INIBIÆO DE ANGIOGéNESE MEDIADA POR ALFA-V-BETA3
GB9625193D0 (en) * 1996-12-04 1997-01-22 Ml Lab Plc Treatment of highly vascular tumours
WO2006127987A2 (en) * 2005-05-25 2006-11-30 Sirtris Pharmaceuticals, Inc. Treatment of eye disorders with sirtuin modulators
WO2009075565A1 (en) * 2007-12-12 2009-06-18 Erasmus University Medical Center Rotterdam Methods for controlling vasculogenesis
US8466278B2 (en) 2008-09-22 2013-06-18 Arcarios B.V. Carboxyethylated cyclodextrin polysulfates useful as medicaments

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5036422A (el) * 1973-08-07 1975-04-05
US4247535A (en) * 1979-11-05 1981-01-27 American Cyanamid Company Modified cyclodextrin sulfate salts as complement inhibitors
US4258180A (en) * 1979-11-05 1981-03-24 American Cyanamid Company C6-Modified cyclodextrin sulfate salts as complement inhibitors
FR2484252A1 (fr) * 1980-05-09 1981-12-18 Chinoin Gyogyszer Es Vegyeszet Procede de preparation de solutions aqueuses de composes organiques biologiquement actifs insolubles ou peu solubles dans l'eau
WO1985002767A1 (en) * 1983-12-21 1985-07-04 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
EP0197571A2 (en) * 1985-03-15 1986-10-15 Janssen Pharmaceutica N.V. Novel derivatives of gamma-cyclodextrin

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4020160A (en) * 1975-08-15 1977-04-26 American Cyanamid Company Cyclodextrin sulfate salts as complement inhibitors
US4066829A (en) * 1976-07-12 1978-01-03 American Cyanamid Company Malto-dextrin poly(H-)sulfates
JPS53109953A (en) * 1977-11-21 1978-09-26 Osamu Asano Pharmaceutical composition having solid tumor controlling action
US4383992A (en) * 1982-02-08 1983-05-17 Lipari John M Water-soluble steroid compounds
US4757056A (en) * 1984-03-05 1988-07-12 Hepar Industries, Inc. Method for tumor regression in rats, mice and hamsters using hexuronyl hexosaminoglycan-containing compositions
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4596795A (en) * 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
JPS61165322A (ja) * 1985-01-14 1986-07-26 Microbial Chem Res Found スパガリン類の注射用凍結乾燥製剤
US4783446A (en) * 1985-11-22 1988-11-08 Neushul Mariculture Incorporated Method for the treatment of AIDS virus and other retroviruses
DE69128292T2 (de) * 1990-01-31 1998-03-26 Ladislav Novotny Verfahren zur Herstellung eines kapillaren Glasröhrchens für miniaturisierte Sensoren

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5036422A (el) * 1973-08-07 1975-04-05
US4247535A (en) * 1979-11-05 1981-01-27 American Cyanamid Company Modified cyclodextrin sulfate salts as complement inhibitors
US4258180A (en) * 1979-11-05 1981-03-24 American Cyanamid Company C6-Modified cyclodextrin sulfate salts as complement inhibitors
FR2484252A1 (fr) * 1980-05-09 1981-12-18 Chinoin Gyogyszer Es Vegyeszet Procede de preparation de solutions aqueuses de composes organiques biologiquement actifs insolubles ou peu solubles dans l'eau
WO1985002767A1 (en) * 1983-12-21 1985-07-04 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
EP0197571A2 (en) * 1985-03-15 1986-10-15 Janssen Pharmaceutica N.V. Novel derivatives of gamma-cyclodextrin

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 83, no. 9, 1st September 1975, abstract no. 79544a, Columbus, Ohio, US; & JP-A-75 36 422 (AJINOMOTO CO., INC.) 05-04-1975 *
CLAIMS NOT SEARCHED: 10-19 *
CLAIMS SEARCHED COMPLETELY: 1-9 *
DIALOG INFORMATION SERVICES, FILE 155 (MEDLINE), accession no. 06630385; D. INGBER et al.: "Inhibition of angiogenesis through modulation of collagen metabolism", & LAB. INVEST., vol. 59, no. 1, July 1988, pp. 44-51 (Cat. D) *
J. CELL. BIOL., vol. 107, no. 6, part 3, December 1988, page 579A, abstract no. 3277; J. FOLKMAN et al.: "A synthetic heparin-mimic modulates angiogenesis and provides a mechanistic model for potentiation of angiostatic steroids" *
J. NATL. CANCER INST., vol. 75, no. 2, August 1985, pages 353-359; W.D. KLOHS et al.: "Collagen-production inhibitors evaluated as antitumor agents" *
JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 72, no. 10, October 1983, pages 1215-1217, American Pharmaceutical Association; S.G. FRANK et al.: "Investigation of the beta-cyclodextrin-hydrocortisone inclusion compound" *
JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 74, no. 9, September 1985, pages 987-990, American Pharmaceutical Association; J. PITHA et al.: "Amorphous water-soluble derivatives of cyclodextrins: nontoxic dissolution enhancing excipients" *
SCIENCE, vol. 230, no. 4732, 1985, pages 1375-1378; R. CRUM et al.: "A new class of steroids inhibits angiogenesis in the presence of heparin or a heparin fragment" *
SCIENCE, vol. 243, no. 4897, 17th March 1989, pages 1490-1493; J. FOLKMAN et al.: "Control of angiogenesis with synthetic heparin substitutes" *

Also Published As

Publication number Publication date
DE68910113D1 (de) 1993-11-25
EP0398925A4 (en) 1991-07-03
IE890125L (en) 1989-07-19
ES2017808A6 (es) 1991-03-01
CN1038304C (zh) 1998-05-13
KR900700114A (ko) 1990-08-11
JPH03502323A (ja) 1991-05-30
JP2995069B2 (ja) 1999-12-27
DK171390D0 (da) 1990-07-17
EP0398925A1 (en) 1990-11-28
IE64346B1 (en) 1995-07-26
DE68910113T2 (de) 1994-03-17
WO1989006536A1 (en) 1989-07-27
DK171390A (da) 1990-08-21
IL88970A (en) 1993-05-13
EP0398925B1 (en) 1993-10-20
CN1036135A (zh) 1989-10-11

Similar Documents

Publication Publication Date Title
ATE242632T1 (de) Verwendung von betulinsäure-derivaten zur behandlung und vorbeugung von melanomen
ES2167377T3 (es) Derivados de piridina farmacologicamente activos y procedimientos para la preparacion de los mismos.
ES2017808A6 (es) Un metodo para prepara una composicion para inhibir el crecimiento indeseado o patologico de celulas o tejidos.
EA200000723A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
DE69311361D1 (de) Zusammensetzungen zur behandlung von glaukoma die prostaglandine und clonidinderivate enthalten
ITMI912296A0 (it) Nuovi pregna 1,4-diene-3,20.dione-16,17-acetal-21-esteri, procedimento per la loro preparazione, composizione e metodi per il trattamento di stati infiammatori
ATE250576T1 (de) Substituierte pyrrolylverbindungen zur behandlung von entzündungen
BG99261A (en) Steroid glycosides for the treatment of hyperchlesterolemia
MX9306960A (es) Composiciones de extracto de corteza de roble, compositiones sinteticasrelacionadas, y metodo para su utilizacion.
DK1119362T3 (da) Anvendelse af tetracyclinderivater til forögelse af interleukin-10-produktion
MX9203811A (es) Esteroides para uso como inmunomoduladores.
DE69710065D1 (de) Androsten-derivate
DE69430816D1 (de) Verwendung von Piperidin-Derivaten in der Behandlung von Schizophrenie
DE60013266D1 (de) Steroidnitrate zur behandlung von oxidativen schädigungen und endothelialer dysfunktion
ES2070276T3 (es) Lactonas macrociclicas inhibidoras del crecimiento celular denominadas combretastatina d-2.
PT1144365E (pt) Inibidores da adesao de celulas mediada por alfa4beta1
NO994330D0 (no) Metode for behandling av en tumor
DE69902523D1 (de) Verwendung von erythropoietin zur behandlung von multiple myelom
ATE271873T1 (de) Verwendung von glukosamin und glukosaminderivaten zur schnellen linderung von juckreiz oder lokalisiertem schmerz
ES2158938T3 (es) Derivados de aminoquinazolina que tienen actividad alfa-antagonistas.
MX9203739A (es) Complejo organico de oro aplicado topicamente.
EA199700241A1 (ru) Новые, определенные по составу смеси ферментов для выделения клеток и лечения ран
ES2061811T3 (es) Uso de compuestos de gamma-oxibutenolido conjugados para tratar ulcera.
FI895084A0 (fi) 3b, 17b-hydroxisubstituerade steroider och steroida naerbeslaektade foereningar.
ATE206052T1 (de) Verwendung von sphingosin-1-phosphat, sphingosin- 1-phosphat-derivaten und/oder deren gemische zur behandlung von entzündlichen hautkrankheiten